Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) shares soared 17.33 percent to close at $28.84 a share Friday. The stock traded between $24.60 and $29.50 on volume of 6.79 million shares traded. The company is scheduled to release results for the fourth quarter and full year 2013 after market close on Thursday, February 27th. Shares of ACADIA Pharmaceuticals are up approximately 15.0 percent in the past year.
Get more information on ACADIA Pharmaceuticals and free access to the in-depth equity report at: www.FiveStarEquities.com/ACAD
Idera Pharmaceuticals Inc. (NASDAQ: IDRA) shares jumped 15.38 percent to close at $6.00 a share Friday. The stock traded between $5.10 and $6.09 on volume 8.01 million shares traded. The company is scheduled to present at the 2014 RBC Capital Markets’ Global Healthcare Conference on Tuesday, February 25th in New York. Shares of Idera Pharmaceuticals are up approximately 30.0 percent year-to-date.
Get more information on Idera Pharmaceuticals free access to the in-depth equity report at: www.FiveStarEquities.com/IDRA
ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS) shares surged 15.53 percent to close at $59.00 a share Friday. The stock traded between $54.55 and $61.30 on volume 6.80 million shares traded. The company reported positive interim results from a recent study of ISIS-SMN Rx in children with spinal muscular atrophy (SMA). Shares of ISIS Pharmaceuticals are up approximately 48.0 percent year-to-date.
Get more information on ISIS Pharmaceuticals and free access to the in-depth equity report at: www.FiveStarEquities.com/ISIS
Retrophin Inc. (NASDAQ: RTRX) shares spiked 14.33 percent to close at $19.47 a share Friday. The stock traded between $17.10 and $19.76 on volume of 699,589 shares traded. The company has announced an agreement to acquire privately held Manchester Pharmaceuticals LLC for a total of $62.5 million. Shares of Retrophin are up approximately 175.0 percent year-to-date.
Get more information on Retrophin and free access to the in-depth equity report at: www.FiveStarEquities.com/RTRX
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Contact: Five Star Equities [email protected]